October 24, 2019 08:27 AM EDTUpdated October 25, 04:07 AM
Bioregnum
R&D
Pharma
Opinion

From $0 to $12B in an in­stant. Here's why bio­phar­ma loves risky Alzheimer's stud­ies

Any­one who is strug­gling to un­der­stand why bio­phar­ma com­pa­nies are will­ing to sink bil­lions in­to piv­otal tri­als built around failed the­o­ries on how to …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times